Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2520-1026
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature ; volume:3 ; number:1 ; day:8 ; month:3 ; year:2019 ; pages:1-11 ; date:12.2019
BMC Rheumatology ; 3, Heft 1 (8.3.2019), 1-11, 12.2019
- Creator
-
Mangoni, Arduino A.
Okaily, Fahdah Al
Almoallim, Hani
Rashidi, Seham Al
Mohammed, Reem Hamdy A.
Barbary, Amal
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s41927-019-0058-7
- URN
-
urn:nbn:de:101:1-2019040222195661303901
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mangoni, Arduino A.
- Okaily, Fahdah Al
- Almoallim, Hani
- Rashidi, Seham Al
- Mohammed, Reem Hamdy A.
- Barbary, Amal
- SpringerLink (Online service)
Other Objects (12)
Monitoring of anti-TNF biological treatments
Stopping Anti-TNF in CD Remitters: Cons
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Anti-TNF, a magic bullet in cancer immunotherapy?
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Predictors of response and anti-TNF drugs comparative efficacy
Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
Predictive biomarkers for anti-TNF alpha therapy in IBD patients
Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study
Der molekulare Wirkmechanismus der anti-TNF Antikörper bei chronisch entzündlichen Darmerkrankungen
Monitoring of anti-TNF biological treatments
Stopping Anti-TNF in CD Remitters: Cons
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Anti-TNF, a magic bullet in cancer immunotherapy?
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Predictors of response and anti-TNF drugs comparative efficacy
Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
Predictive biomarkers for anti-TNF alpha therapy in IBD patients
Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study
Der molekulare Wirkmechanismus der anti-TNF Antikörper bei chronisch entzündlichen Darmerkrankungen
Monitoring of anti-TNF biological treatments
Stopping Anti-TNF in CD Remitters: Cons
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Anti-TNF, a magic bullet in cancer immunotherapy?
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Predictors of response and anti-TNF drugs comparative efficacy
Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
Predictive biomarkers for anti-TNF alpha therapy in IBD patients
Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study